Press Releases

Press Releases

Takeda Pharmaceutical Company Limited will present data on ADCETRIS® (brentuximab vedotin) in Hodgkin lymphoma at the 10th International Symposium on Hodgkin Lymphoma (ISHL), October 22 – 25, 2016 in Cologne, Germany. Four studies on brentuximab vedotin will be presented by Takeda during the meeting. Takeda is the Jubilee sponsor of…

Press Releases

Researchers looking to quickly and confidently identify expression biomarkers using highly challenging clinical research samples now have access to Thermo Fisher Scientific’s new Clariom Pico assays—the next generation family of transcriptome profiling tools designed to provide a fast and simple path to discovery. The two Clariom brand of assays (Clariom…

Press Releases

Omeros Corporation today announced positive data from the company’s Phase 2 clinical trial of OMS721 for the treatment of kidney disorders, none of which currently have an approved treatment and all of which frequently lead to end-stage renal disease and dialysis. Statistical significance (p ≤ 0.017) was achieved on key…

Press Releases

Antibe Therapeutics Inc., is pleased to provide an update on it second pipeline drug, ATB-352, a potent pain-killer intended for the relief of acute, severe pain. Recently completed pre-clinical studies have now demonstrated that ATB-352, unlike opiate drugs, does not bind to opioid receptors and therefore does not pose a…

Press Releases

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) approved the Lucentis® (ranibizumab injection) 0.5 mg prefilled syringe (PFS) as a new method of administering the medicine. Like the Lucentis 0.5 mg vial, the 0.5 mg PFS is approved to treat people…

Press Releases

ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, October 28, 2016, to discuss ImmunoGen's financial results for the three-month period and fiscal year ended September…

Press Releases

Trevi Therapeutics, Inc., a late-stage clinical development company developing oral Nalbuphine®ER for chronic pruritus conditions, today announced positive results from its Phase 2 trial for the treatment of moderate to severe prurigo nodularis. Prurigo nodularis (PN), a severely pruritic dermatological condition characterized by itchy skin papules and nodules, has significant…

Press Releases

CohBar, Inc., an innovative biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat diseases associated with aging, today announced the discovery of a large number of new biologically active peptides encoded within the genome of the mitochondria, together with the filing of 25 new provisional patent applications. The…

Press Releases

Certara®, the leading provider of decision support technology and consulting services for optimizing drug development and improving health outcomes, today announced that Peking Union Medical College (PUMC) Hospital in Beijing, China, and Keio University in Tokyo, Japan have become Phoenix® Centers of Excellence. Phoenix is the most advanced, intuitive, and…

Press Releases

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and the Dana-Farber Cancer Institute today announced a preclinical research collaboration focused on lung cancer. A team of scientists led by Pasi A. Jänne, MD, PhD, Director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; Scientific Director, Belfer Center for Applied Cancer Science;…